Driving

sustainability
in aquaculture
SHRIMP BREEDING, HUSBANDRY & NUTRITION
HATCH INDIA 2023
GENOMIC SELECTION AS A TOOL FOR
DYNAMIC AND DIVERSE CHALLENGES
Oscar Hennig

This document and any information contained within it is

the property of Benchmark Holdings Plc and its Affiliates
GENETICS ADVANCED NUTRITION HEALTH
Benchmark at a glance: mission critical products and solutions
Unique Specialised Global

GENETICS Farming efficiency

ADVANCED NUTRITION
Animal growth

Salmon Shrimp Bass/bream Tilapia

HEALTH Animal health & welfare

Technical experts always by your side

Commercial and R&D Employing more than Customers in

Group Revenue (FY22)
operations
£158.3m 800 70+
26countries people worldwide Countries

2
 Advanced Nutrition - INVE
Hatchery, nursery and farm

PRODUCTS ADVANCED
NUTRITION

• Live feed: Artemia

• Hatchery and nursery diets
• Probiotics
• Environmental treatments
600+
customers in 70+ countries
served directly and through
distributors

500
employees globally

3
Present Challenges
Penaeus vannamei
• Global aquaculture value:
• US$15 billion per year
• ~40% production lost to disease
• Taura; WSSV; YHD; AHPND; EHP; WFD;
DIV1;TPD.……………………………………………
……………………………………………………………
…………………IHNI?
 Benchmark Genetics Shrimp

GENETICS

SHRIMP, THAILAND - PRACHUAP

• 40K breeders

SHRIMP, USA
• 60M PL / 96K breeders (2021)
• Project double capacity ongoing

SHRIMP, VIETNAM - PHAN RANG

• R&D farm
SHRIMP, COLOMBIA SHRIMP&LAB - ECUADOR
• 20M PL/month
• 1,500M Nauplii/month
6 • 250 families & 20K breeders (2016)
Benchmark Genetics COLOMBIA: Product Development

• Punta Canoas: SPF & SPR

• Nucleus Breeding Center (NBC)
• Multiplication Center (BMC)
• Commercial breeders for LATAM

• Pacific Coast: Genomic testing facility

• Sentinel testing
• Recording both phenotype and genotype

• Bogotá: Disease testing facility

• Single pathogen challenge testing
• WSSV; AHPNH (EMS)
• Backup facility
Benchmark Shrimp Breeding: DNA tools

2016: 192 SNP chip

• Parental assignment

2018: 15K custom SNP

• Benchmark Genetics & NeoGen

2019: ~40K
• Additional SNPs by whole genome sequencing
2023
• Finishing a multispecies SNP

8
Parental Assignment (192 SNP) & Principal Component Analysis (40K SNP)

9
Genomic Selection (40K SNP)

Family and Individual

• Challenge test siblings
• Genomic selection individuals

Utilize the full genetic variance

• Increased selection differentials
• Reduced accumulation of inbreeding
• Increased accuracy of genetic
predictors (EBV)

10
 Benchmark Genetics Shrimp: Product Development & Validation
• Thailand
• Local selection
• Vietnam
• Challenge test
• EHP/WFD
• IMNV
• R&D Farm
• India
• Commercial lines validation

11
 Benchmark Genetics Shrimp: Product Development & Validation
Challenge test: R&D Farm: High disease prevalent area
• EHP/WFD: 3 trials • Four trials:
• Two commercial lines (validation) • Three commercial lines (validation)
• One Breeding Nucleus (development) • One Breeding Nucleus (development)
• Genomic family selection • Genomic family selection

12
Benchmark Genetics Shrimp: Product Validation - EHP & WFD

Challenge Test 1 & 2

52 Negative control. Non infected. Same animals

52 BMK commercial line.

52 BMK commercial line

52 BMK commercial line

Daily mortality recorded from day 0 to harvest

Pre-challenge EHP WFD Post-Challenge Harvest

14 days 7 days 2 days 42 days Survival and weight
 Benchmark Genetics Shrimp: Product Validation - EHP & WFD trials 1 & 2

14
 Benchmark Genetics Shrimp INDIA: Validation
Benchmark signed an agreement with Sandhya Aqua for the validation trial in December 2022.
My special thanks to Mr. Chowdary, Sandhya Aqua, for his support.

• The new lines for validation were sent to India in February 2023.
• The PL were delivered to farms from May 2023.
• We have encouraging results from the farms.

No. of breeders No. of ponds No. of ponds

Lines No. of PL sold PL sold in %
imported stocked harvested

BMK B101 (Green) 250 6,110,000 36% 13 8

BMK B301 (White) 250 11,050,130 64% 32 22

Total 500 17,160,130 100% 45 30

15
 Benchmark Genetics Shrimp: Product Development – Sentinel Trials

Challenge test EHP & WFD R&D Farm

• Genomic family selection • Genomic family selection.

16
Benchmark Genetics Shrimp: Product Development – EHP + WFD
Family Challenge Test

342 342 Negative control. Non infected. Same animals

342 342 342

342

342 342 342 342

Pleopods and weigh sample during and at lab
trial termination
DOC 58 – PL-10

Daily mortality recorded from day 0 to harvest

Pre-challenge EHP WFD Post-Challenge Harvest

14 days 7 days 2 days 35 days Survival and weight
 Benchmark Genetics Shrimp: Product Development
Sentinel Trial - Lab

Infected group: 8% above 10g (DOC 58)

18
Benchmark Genetics Shrimp: Product Development
Sentinel Trial - Farm

Pleopods and weigh sample at farm pond trial Range of the weights for both ponds: 1,003
termination shrimps sampled/pond
DOC 92 – PL-10
Genomic Selection: The Best of Both Worlds

• Benchmark Genetics routinely tests sentinels of the breeding nucleus in commercial environments,
enabling selection for optimal farm performance, while retaining highest levels of biosecurity

Performance data from commercial farm Genomic selection used to accurately select high
environments recorded and tissue samples taken for performance breeders kept in biosecure breeding
genotyping nucleus
 SHRIMP FIT FOR THEIR ENVIRONMENT
ధన్యవాదాలు!

Contact us
Scan me!
Balachandar: +91 7305402705 / +91 7550207294
Disclaimer

Confidentiality
This document and the information contained within it, is commercially sensitive and therefore strictly confidential. It is intended
solely for internal update.
You are hereby notified that any disclosure, copying, distribution or taking action in relation to the contents of this material,
without the prior written permission of Benchmark Holdings plc, is strictly prohibited and infringes the intellectual property rights
of Benchmark Holdings plc.

Disclaimer
Benchmark takes no responsibility for any claims that may arise from information contained in this document.
This document contains forward looking statements. These forward-looking statements reflect the knowledge and information
available to Benchmark during the preparation and up to the publication of this document. By their very nature, these statements
depend upon circumstances and relate to events that may occur in the future thereby involve a degree of uncertainty, and it is
acknowledged that the circumstances contemplated by these forward looking statements may not be realised. These forward-
looking statements speak only as at the date of this presentation, and each of the Company, and its respective agents,
employees, advisers or affiliates, expressly disclaim any obligation or undertaking to update or revise any forward-looking
statements contained herein.
Copyright ©️ 2021 Benchmark Holdings plc. This document and the information contain within is the copyright of Benchmark
Holdings plc. All rights reserved. Benchmark and associated logos are registered trademarks of Benchmark Holdings plc.

22